Fisetin Stick Pack (1 Box)

 In a landmark 2018 study, researchers screened 10 flavonoid compounds for senolytic activity in senescent mouse and human cells, and fisetin emerged as the most potent. In mice, both acute and intermittent fisetin treatment reduced senescence markers across multiple tissues. Most notably, administering fisetin to wild-type mice late in life restored tissue homeostasis, reduced age-related pathology, and extended both median and maximum lifespan. This is animal-model evidence, not a human outcome, but it's the study that established fisetin's reputation and launched the current wave of human trials.

In vitro research shows fisetin's senolytic action appears to selectively target senescent cells while sparing healthy ones. Researchers describe fisetin as acting on specific "senescent cell anti-apoptotic pathways" (SCAPs), essentially proteins that senescent cells rely on to resist their own natural cell death. This cell-culture-level selectivity is what distinguishes a true senolytic from a generic cytotoxic compound, and it's the mechanistic basis researchers cite for why fisetin can be studied without expecting broad, indiscriminate cell death.

Yes, a study in old mice found that intermittent fisetin supplementation improved arterial function by reducing cellular senescence in blood vessels. Using a genetic mouse model that allowed researchers to selectively remove senescent cells, they confirmed the improvement was specifically due to senolysis (clearing senescent cells), fisetin-treated mice showed lower arterial stiffness, better endothelium-dependent dilation, and reduced oxidative stress, mediated by increased nitric oxide availability. This is a well-designed animal study that isolates the mechanism, but it hasn't yet been replicated as a vascular outcome in a human trial.

Yes, this is an important nuance often missed in fisetin discussions. The foundational 2018 study that established fisetin's reputation for extending lifespan actually used continuous dietary supplementation, not a short pulse. Researchers fed mice a diet containing fisetin (500 mg/kg of diet) continuously, starting at 85 weeks of age (roughly equivalent to a 75-year-old human), and sustained that exposure. This chronic-exposure protocol is what produced the study's headline finding: extended median and maximum lifespan in aged mice.

Yes. The same study also tested chronic, diet-based fisetin exposure in a separate mouse model of accelerated aging (progeroid mice) and found it reduced markers of cellular senescence and SASP (senescence-associated inflammatory factors) across multiple tissues, alongside reduced markers of oxidative stress in the liver.

This appears to be a practical and safety consideration for human translation rather than evidence that chronic dosing doesn't work. Later, more targeted animal studies (on vascular function and skeletal muscle specifically) intentionally used intermittent dosing to isolate the senolytic mechanism and to mirror the dosing paradigm used in human clinical trials — and trial designers have explicitly cited reduced side-effect risk and fewer drug interactions as reasons for choosing intermittent human protocols. In other words: pulsed dosing became the human standard largely for tolerability and trial-design reasons, not because chronic dosing was shown to be inferior in animals.